Go Pro
→ 'How Much Can I Actually Spend Each Year With $2.5M Saved?' (From SmartAsset) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$11.11
+1.1%		$10.18
$8.67
▼
$13.00
$2.64B1.23,166 shs3,133 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$24.41
+2.5%		$25.96
$21.02
▼
$42.21
$2.92B0.091.13 million shs1.64 million shs
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
$6.65
$7.03
$5.80
▼
$12.61
$704.63M1.21,634 shs16,707 shs
Precigen, Inc. stock logo
PGEN
Precigen
$8.59
+6.7%		$6.88
$2.99
▼
$8.98
$3.06B1.024.68 million shs9.59 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
-0.94%+2.81%+0.55%+17.54%-7.77%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
+0.98%+2.10%-8.07%-32.30%-13.48%
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
0.00%+0.61%-6.99%-16.09%-8.90%
Precigen, Inc. stock logo
PGEN
Precigen
+3.07%+2.03%+15.83%+53.33%+121.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$11.11
+1.1%		$10.18
$8.67
▼
$13.00
$2.64B1.23,166 shs3,133 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$24.41
+2.5%		$25.96
$21.02
▼
$42.21
$2.92B0.091.13 million shs1.64 million shs
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
$6.65
$7.03
$5.80
▼
$12.61
$704.63M1.21,634 shs16,707 shs
Precigen, Inc. stock logo
PGEN
Precigen
$8.59
+6.7%		$6.88
$2.99
▼
$8.98
$3.06B1.024.68 million shs9.59 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
-0.94%+2.81%+0.55%+17.54%-7.77%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
+0.98%+2.10%-8.07%-32.30%-13.48%
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
0.00%+0.61%-6.99%-16.09%-8.90%
Precigen, Inc. stock logo
PGEN
Precigen
+3.07%+2.03%+15.83%+53.33%+121.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
0.00
N/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.85
Moderate Buy$49.73103.73% Upside
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
2.00
HoldN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
2.83
Moderate Buy$13.6759.17% Upside

Current Analyst Ratings Breakdown

Latest OXBDF, NAMS, BVNRY, and PGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/25/2026
Precigen, Inc. stock logo
PGEN
Precigen
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
9/24/2026
Precigen, Inc. stock logo
PGEN
Precigen
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
9/8/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$52.00
8/6/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$51.00 ➝ $50.00
8/5/2026
Precigen, Inc. stock logo
PGEN
Precigen
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$14.00 ➝ $18.00
8/5/2026
Precigen, Inc. stock logo
PGEN
Precigen
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/3/2026
Precigen, Inc. stock logo
PGEN
Precigen
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$14.00
7/22/2026
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
7/20/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$58.00
7/20/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00
7/20/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 9/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$945.43M2.79$1.35 per share8.24$8.20 per share1.35
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$7.12M409.74N/AN/A$5.97 per share4.09
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
$164.59M4.28N/AN/A$0.62 per share10.73
Precigen, Inc. stock logo
PGEN
Precigen
$9.68M316.22N/AN/A$0.06 per share143.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
$208.23M$0.9911.22N/AN/A24.36%11.97%10.55%N/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$203.82M-$2.16N/AN/AN/A-3,644.21%-34.81%-31.50%11/4/2026 (Estimated)
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
-$46.74MN/AN/A51.15N/AN/AN/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
-$250.64M-$1.04N/A11.76N/A-183.98%423.75%84.39%11/12/2026 (Estimated)

Latest OXBDF, NAMS, BVNRY, and PGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/21/2026Q2 2026
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A$0.46N/A$0.46N/A$316.47 million
8/5/2026Q2 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.4819-$0.52-$0.0381-$0.52$2.83 million$3.70 million
8/4/2026Q2 2026
Precigen, Inc. stock logo
PGEN
Precigen
-$0.0121$0.05+$0.0621$0.05$27.98 million$54.98 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/AN/AN/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/AN/AN/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A
6.53
3.91
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
9.03
9.03
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
2.15
4.58
3.89

Institutional Ownership

CompanyInstitutional Ownership
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/A
Precigen, Inc. stock logo
PGEN
Precigen
33.51%

Insider Ownership

CompanyInsider Ownership
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
N/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
12.74%
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/A
Precigen, Inc. stock logo
PGEN
Precigen
41.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bavarian Nordic stock logo
BVNRY
Bavarian Nordic
1,692237.80 millionN/ANot Optionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
100119.54 million104.31 millionOptionable
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
891105.96 millionN/ANot Optionable
Precigen, Inc. stock logo
PGEN
Precigen
47356.51 million208.92 millionOptionable

Recent News About These Companies

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
 |  zacks.comhttps://www.zacks.com/stock/news/2998371/pgen-vs-irwd-which-biotech-stock-offers-better-growth-potential?cid=cs-stocknewsapi-ft-analyst_blog|most_popular_stocks-2998371
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pgen-vs-irwd-biotech-stock-150800736.html
Precigen: The FDA's Platform Technology Designation And The Institutional Crossover Effect
 |  seekingalpha.comhttps://seekingalpha.com/article/4951004-precigen-the-fdas-platform-technology-designation-and-the-institutional-crossover-effect
Precigen (NASDAQ:PGEN) Hits New 12-Month High - Here's What Happened
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-precigen-nasdaq-pgen-hits-new-12-month-high-heres-what-happened-2026-09-30/
Head to Head Contrast: Emergent Biosolutions (NYSE:EBS) vs. Precigen (NASDAQ:PGEN)
September 30 at 4:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068357
Critical Review: TScan Therapeutics (NASDAQ:TCRX) vs. Precigen (NASDAQ:PGEN)
September 29 at 5:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31063385
Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?
September 29 at 1:59 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/precigen-pgen-gets-fda-recognition-015839357.html
Precigen (NASDAQ:PGEN) Shares Gap Up After Analyst Upgrade
September 27 at 3:34 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31054493
Bank of America Corp DE Buys 1,848,414 Shares of Precigen, Inc. $PGEN
September 27 at 3:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-buys-1848414-shares-of-precigen-inc-pgen-2026-09-27/
Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap?
September 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/precigen-pgen-gains-fda-platform-170940636.html
B Riley Securities initiates coverage of Precigen at buy
September 26, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/b-riley-securities-initiates-coverage-of-precigen-at-buy/ar-AA2cZ9VI
B. Riley Financial Upgrades Precigen (NASDAQ:PGEN) to "Strong-Buy"
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-b-riley-financial-upgrades-precigen-nasdaq-pgen-to-strong-buy-2026-09-26/
Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies
September 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/precigen-pgen-secures-fda-platform-161139077.html
Precigen (NASDAQ:PGEN) Shares Gap Up - Here's What Happened
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-precigen-nasdaq-pgen-shares-gap-up-heres-what-happened-2026-09-25/
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
September 24, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2995241/can-pgen-s-adenoverse-pipeline-create-growth-beyond-papzimeos?cid=cs-stocknewsapi-ft-analyst_blog|quick_take-2995241
Corient Private Wealth LP Sells 577,406 Shares of Precigen, Inc. $PGEN
September 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-sells-577406-shares-of-precigen-inc-pgen-2026-09-24/
Precigen (NASDAQ:PGEN) Hits New 12-Month High - What's Next?
September 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31042211
Precigen (NASDAQ:PGEN) Hits New 1-Year High - Time to Buy?
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-precigen-nasdaq-pgen-hits-new-1-year-high-time-to-buy-2026-09-23/
Precigen, Inc. (NASDAQ:PGEN) Receives Average Rating of "Moderate Buy" from Brokerages
September 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31041888
Precigen, Inc. (NASDAQ:PGEN) Given Consensus Recommendation of "Moderate Buy" by Analysts
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-precigen-inc-nasdaq-pgen-given-consensus-recommendation-of-moderate-buy-by-analysts-2026-09-23/
Precigen's AdenoVerse Receives FDA Platform Technology Designation
September 22, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/precigen-apos-adenoverse-receives-fda-131303607.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bavarian Nordic stock logo

Bavarian Nordic OTCMKTS:BVNRY

$11.11 +0.12 (+1.09%)
As of 03:19 PM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$24.41 +0.60 (+2.52%)
Closing price 03:59 PM Eastern
Extended Trading
$24.34 -0.07 (-0.30%)
As of 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Oxford BioMedica stock logo

Oxford BioMedica OTCMKTS:OXBDF

$6.65 0.00 (0.00%)
As of 09/29/2026

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Precigen stock logo

Precigen NASDAQ:PGEN

$8.59 +0.54 (+6.66%)
Closing price 03:59 PM Eastern
Extended Trading
$8.54 -0.05 (-0.54%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas